A groundbreaking study published in Eurosurveillance has revealed compelling evidence that influenza vaccination provides a significant protective effect against cardiovascular events such as heart attacks and strokes, even in individuals who contract influenza despite being vaccinated. This new research sheds light on the dual benefits of the flu vaccine: not only preventing virus infection but also reducing the severe cardiovascular risks associated with influenza disease.
It is well documented that infection with the influenza virus precipitates an acute-phase inflammatory response that can impair vascular function and destabilize atherosclerotic plaques. These pathological changes markedly increase the short-term risk of cardiovascular complications following infection. Prior research has predominantly emphasized that vaccination reduces these cardiac and cerebrovascular events by averting influenza infection. However, the study led by Croci et al. ventures into previously uncharted territory by quantifying the elevated cardiovascular risk after influenza infection and examining whether the vaccine mitigates these risks even among those who contract the virus post-vaccination.
The Danish cohort study included 1,221 adults aged 40 and above who experienced their first hospital admission for either myocardial infarction or stroke within a year of lab-confirmed influenza infection. Spanning nine consecutive influenza seasons from 2014 to 2025, the investigation leveraged Denmark’s comprehensive health registries to intricately link PCR-confirmed influenza cases with hospitalization, vaccination, and mortality data using unique personal identifiers, enabling precise longitudinal tracking.
Participants were predominantly elderly, with a median age of 75, reflective of the high cardiovascular risk population targeted. Among them, 65% were admitted due to stroke and the remaining 35% following a heart attack. Notably, approximately half of laboratory-confirmed influenza infections occurred in participants who had received the influenza vaccine for that particular season. This distinctive aspect allowed researchers to scrutinize the vaccine’s protective efficacy beyond preventing infection, focusing on outcomes post-infection.
Employing a self-controlled case series design, the researchers used conditional Poisson regression models to estimate incidence rate ratios for cardiovascular events surrounding the time of influenza infection within the same individual. This approach effectively controls for individual-level confounders such as genetic predispositions, underlying comorbidities, and socioeconomic factors, which often complicate observational studies. The methodology also accounted for potential reverse causality by excluding events occurring in the two weeks prior to influenza testing, as symptoms might have prompted diagnostic testing rather than the infection provoking cardiovascular events.
The results were striking. The immediate seven-day interval following laboratory confirmation of influenza infection bore the highest risk for first-time hospitalizations due to heart attack and stroke. Specifically, the risk of stroke was elevated approximately threefold, while the risk of myocardial infarction surged fivefold compared to baseline periods outside this acute phase. This underscores the severity of the cardiovascular burden triggered by influenza infection in vulnerable populations.
Remarkably, influenza vaccination halved this elevated risk among vaccinated individuals who contracted influenza, demonstrating a substantial protective effect of the vaccine against severe cardiovascular sequelae beyond simply preventing infection. This novel finding suggests that the immunological benefits of the vaccine may modulate the inflammatory and thrombotic pathways activated by influenza, consequently attenuating the potential for cardiovascular events triggered by infection.
It is important to note that the study did not differentiate between vaccine formulations or account for variations in vaccine strain matching and effectiveness across the seasons studied. These factors can influence overall vaccine efficacy and might affect how strongly vaccination protects against post-influenza cardiac complications. Additionally, analyses stratified by vaccination timing or sex differences were not included, which could provide further insights into optimizing vaccination strategies.
The epidemiological setting, comprehensive healthcare infrastructure, and vaccination policies in Denmark provide a unique backdrop for this research, but caution is warranted in extrapolating these results to countries with differing influenza epidemiology or healthcare systems. Nevertheless, the implications of these findings are far-reaching. If corroborated by further studies in diverse populations and settings, the evidence would bolster current recommendations prioritizing influenza vaccination for individuals at elevated risk of cardiovascular disease.
The study authors emphasize the importance of communicating the dual protective benefits of influenza vaccination to the public and healthcare providers alike. Such messaging could enhance vaccine uptake among high-risk groups by framing vaccination not merely as an infection prevention tool but also as a crucial intervention to reduce heart attack and stroke risk associated with influenza infection.
Public health authorities may also find value in integrating these findings into economic evaluations of vaccination programs. By quantifying the vaccine’s additive effect in preventing cardiovascular complications—a significant contributor to morbidity, mortality, and healthcare expenditure—the argument for expanding influenza vaccination coverage gains substantial economic and clinical weight.
This research also opens avenues for mechanistic investigations into how influenza vaccination modulates host inflammatory and coagulation responses following infection. Understanding these underlying biological pathways could guide the development of adjunctive therapeutic strategies to further mitigate cardiovascular risks triggered by respiratory viral infections.
In summary, Croci et al. provide robust epidemiological evidence supporting influenza vaccination not only as a means to prevent viral infection but also as a significant intervention to reduce the risk of acute cardiovascular events precipitated by influenza infection. This dual role could transform public health vaccination campaigns and clinical guidelines, especially for populations susceptible to cardiac and cerebrovascular diseases.
Given the heightened cardiovascular risk during influenza seasons illuminated by this study, clinicians should advocate more strongly for vaccination, particularly in older adults and those with underlying cardiovascular conditions. Enhanced vaccination strategies combined with awareness of post-influenza cardiovascular risks could improve outcomes and reduce hospitalizations, underscoring the vaccine’s critical role within comprehensive cardiovascular disease prevention.
Further research should focus on validating these findings globally, exploring vaccine-specific factors influencing protection against cardiovascular sequelae, and elucidating the immunological mechanisms underpinning vaccine-mediated risk attenuation. Such endeavors will be pivotal in crafting precise, evidence-based recommendations that maximize the protective benefits of influenza vaccination.
Subject of Research: People
Article Title: Influenza vaccine could protect against heart attack and stroke even among people who get infected
News Publication Date: 2-Apr-2026
Web References: https://doi.org/10.2807/1560-7917.ES.2026.31.13.2500706
Keywords: Influenza, Myocardial infarction, Cerebrovascular disorders, Epidemiology, Infectious diseases, Public health, Vaccination, Flu vaccines
Tags: acute-phase inflammation influenzaatherosclerotic plaque destabilization fluDanish cohort influenza studyflu vaccine benefits beyond infectionflu vaccine cardiovascular protectionflu vaccine effectiveness in infected individualsflu vaccine stroke and heart attack preventioninfluenza and vascular function impairmentinfluenza infection cardiovascular riskinfluenza vaccination heart attack riskpost-influenza cardiovascular eventsstroke prevention flu vaccine
